(Q24244954)

1

0 references

V Demicheli

2

0 references

C Di Pietrantonj

3

0 references

AR Harnden

4

0 references

T Jefferson

5

0 references

NJ Matheson

6

0 references

A Rivetti

Cochrane Database of Systematic Reviews

7

0 references

publication date

25 January 2006

0 references

published in

0 references

cites work

Evaluation of a Neuraminidase-Specific Influenza A Virus Vaccine in Children: Antibody Responses and Effects on Two Successive Outbreaks of Natural Infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Single-Dose Trials of Monovalent A/New Jersey/76 (Hsw1N1) Influenza Virus Vaccine in Children in Durham, North Carolina

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Monovalent Inactivated A/New Jersey/8/76 (Hsw1N1) Vaccine in Healthy Children Aged Three to Five Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Comparison of live attenuated cold-adapted and avian-human influenza A/Bethesda/85 (H3N2) reassortant virus vaccines in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Efficacy of live attenuated influenza A/Scotland/74 (H3N2) virus vaccine against challenge with influenza A/Victoria/3/75 (H3N2) virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Clinical Trials with Inactivated Monovalent (A/New Jersey/76) and Bivalent (A/New Jersey /76-A/Victoria/75) Influenza Vaccines in Los Angeles Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Use of influenza A virus vaccines in seronegative children: live cold-adapted versus inactivated whole virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Influenza B Virus Vaccines in Children and Adults: Adverse Reactions, Immune Response, and Observations in the Field

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Reactogenicity and Immunogenicity of Bivalent Influenza Vaccine in One- and Two-Dose Trials in Children: A Summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

A Controlled Double-Blind Comparison of Reactogenicity, Immunogenicity, and Protective Efficacy of Whole-Virus and Split-Product Influenza Vaccines in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Comparison of monovalent and trivalent live attenuated influenza vaccines in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

An Attenuated Influenza Virus Vaccine: Reactogenicity, Transmissibility, Immunogenicity, and Protective Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Reactivity and Immunogenicity of Monovalent A/New Jersey/76 Influenza Virus Vaccines in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

A Clinical Trial with Monovalent Influenza A/New Jersey/76 Virus Vaccine in Preschool and School-Age Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Reactions and serologic responses after administration of inactivated monovalent influenza A/swine virus vaccines. II. Immunization of children with influenza A/New Jersey/X-53 virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Reactions and Serologic Responses after Administration of Inactivated Monovalent Influenza A/Swine Virus Vaccines. I. Immunization of Children and Adults with Influenza A/Shope Virus Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration. Summary of clinical trials of influenza vaccines--I

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Vaccines for preventing influenza in people with asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Amantadine and rimantadine for preventing and treating influenza A in adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Vaccines for preventing influenza in healthy adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Influenza vaccine for patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Immunogenicity and safety of influenza vaccination in 3- to 6-year-old children with a two dose immunisation schedule

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

A/New Jersey/76 influenza vaccine trial in seronegative schoolchildren: Comparison of a subunit vaccine with a whole-virus vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Influenza vaccine in immunogenically naive healthy infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Class-specific antibody responses in school children vaccinated with an A/Brazil/11/78 (H1N1)-like recombinant influenza virus prepared from the A/Leningrad/134/57 paediatric cold-adapted donor strain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Evaluation in children of cold-adapted influenza B live attenuated intranasal vaccine prepared by reassortment between wild-type B/Ann Arbor/1/86 and cold-adapted B/Leningrad/14/55 viruses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Comparison of live attenuated and inactivated influenza vaccines in schoolchildren in Russia: I. Safety and efficacy in two Moscow schools, 1987/88

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Safety and immunogenicity of a purified haemagglutinin antigen in very young high-risk children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Clinical reactions and serologic response following inactivated monovalent influenza type B vaccine in young children and infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Spared an influenza pandemic for another year?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Safety of influenza vaccines in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

A comparison of live and killed influenza-virus vaccines. Report to the Medical Research Council's Committee on Influenza and other Respiratory Virus Vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Controlled trial of inactivated influenza vaccine containing the a-Hong Kong strain during an outbreak of influenza due to the a-England-42-72 strain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM? vaccines and conventional vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

A prospective, Internet-based study of the effectiveness and safety of influenza vaccination in the 2001–2002 influenza season

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Simultaneous administration of live, attenuated influenza A vaccines representing different serotypes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Developments in mucosal influenza virus vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: safety, immunogenicity and dose-response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Assessment of effectiveness of Vaxigrip

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Are we ready for universal influenza vaccination in paediatrics?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Prophylactic effect of inactivated influenza vaccine on young children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Failure of inactivated influenza A vaccine to protect healthy children aged 6-24 months

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Safety of the trivalent, cold-adapted influenza vaccine (CAIV-T) in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Immunisation against influenza with a new subunit vaccine tested on children at risk (author's transl)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Influenza and the rates of hospitalization for respiratory disease among infants and young children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

The Japanese experience with vaccinating schoolchildren against influenza

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Does influenza vaccination prevent asthma exacerbations in children?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Efficacy of intranasal virosomal influenza vaccine in the prevention of recurrent acute otitis media in children.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Summary of Clinical Trials of Inactivated Influenza Vaccine--1978

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Various factors associated with the manifestation of influenza-like illness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Modification of an Outbreak of Influenza in Tecumseh, Michigan by Vaccination of Schoolchildren

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Evaluation of monovalent and polyvalent influenza vaccines during an epidemic of type A2 and B influenza

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Prevention of otitis media in children with live attenuated influenza vaccine given intranasally

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Incidence of influenza in Finnish children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Socioeconomic impact of influenza on healthy children and their families

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Evaluation of a live, attenuated recombinant influenza vaccine in high school children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Cell-mediated immune responses to the hemagglutinin and neuraminidase antigens of influenza A virus after immunization in humans

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Evaluation of a cold-adapted influenza B/Texas/84 reassortant virus (CRB-87) vaccine in young children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Three year follow up study of national influenza vaccination practices in Japan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Vaccinations May Induce Diabetes-Related Autoantibodies in One-Year-Old Children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Risk factors associated with severe influenza infections in childhood: implication for vaccine strategy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

Recommendations for influenza immunization of children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021

The impact of influenza epidemics on mortality: introducing a severity index.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004879.PUB2

7 January 2021